265 related articles for article (PubMed ID: 25657018)
1. Metabolomic markers of altered nucleotide metabolism in early stage adenocarcinoma.
Wikoff WR; Grapov D; Fahrmann JF; DeFelice B; Rom WN; Pass HI; Kim K; Nguyen U; Taylor SL; Gandara DR; Kelly K; Fiehn O; Miyamoto S
Cancer Prev Res (Phila); 2015 May; 8(5):410-8. PubMed ID: 25657018
[TBL] [Abstract][Full Text] [Related]
2. Metabolic profiling of potential lung cancer biomarkers using bronchoalveolar lavage fluid and the integrated direct infusion/ gas chromatography mass spectrometry platform.
Callejón-Leblic B; García-Barrera T; Grávalos-Guzmán J; Pereira-Vega A; Gómez-Ariza JL
J Proteomics; 2016 Aug; 145():197-206. PubMed ID: 27255828
[TBL] [Abstract][Full Text] [Related]
3. Exploratory investigation of plasma metabolomics in human lung adenocarcinoma.
Wen T; Gao L; Wen Z; Wu C; Tan CS; Toh WZ; Ong CN
Mol Biosyst; 2013 Sep; 9(9):2370-8. PubMed ID: 23857124
[TBL] [Abstract][Full Text] [Related]
4. Metabolomic profiling of human lung tumor tissues - nucleotide metabolism as a candidate for therapeutic interventions and biomarkers.
Moreno P; Jiménez-Jiménez C; Garrido-Rodríguez M; Calderón-Santiago M; Molina S; Lara-Chica M; Priego-Capote F; Salvatierra Á; Muñoz E; Calzado MA
Mol Oncol; 2018 Oct; 12(10):1778-1796. PubMed ID: 30099851
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis of lung tumor types based on metabolomic profiles in lymph node aspirates.
Sappington D; Helms S; Siegel E; Penney RB; Jeffus S; Bartter T; Bartter T; Boysen G
Cancer Treat Res Commun; 2018; 14():1-6. PubMed ID: 30104001
[TBL] [Abstract][Full Text] [Related]
6. UPLC-MS-based metabolomics reveals metabolic dysregulation in ALDH1A1-overexpressed lung adenocarcinoma cells.
Wang Y; Wang CH; Zhang YF; Zhu L; Lei HM; Tang YB
Metabolomics; 2019 Mar; 15(4):52. PubMed ID: 30911937
[TBL] [Abstract][Full Text] [Related]
7. Metabolite Profiles of the Serum of Patients with Non-Small Cell Carcinoma.
Mazzone PJ; Wang XF; Beukemann M; Zhang Q; Seeley M; Mohney R; Holt T; Pappan KL
J Thorac Oncol; 2016 Jan; 11(1):72-8. PubMed ID: 26762741
[TBL] [Abstract][Full Text] [Related]
8. Metabolic and lipidomic characterization of malignant pleural effusion in human lung cancer.
Yang Z; Song Z; Chen Z; Guo Z; Jin H; Ding C; Hong Y; Cai Z
J Pharm Biomed Anal; 2020 Feb; 180():113069. PubMed ID: 31884394
[TBL] [Abstract][Full Text] [Related]
9. A metabolomic approach to lung cancer.
Hori S; Nishiumi S; Kobayashi K; Shinohara M; Hatakeyama Y; Kotani Y; Hatano N; Maniwa Y; Nishio W; Bamba T; Fukusaki E; Azuma T; Takenawa T; Nishimura Y; Yoshida M
Lung Cancer; 2011 Nov; 74(2):284-92. PubMed ID: 21411176
[TBL] [Abstract][Full Text] [Related]
10. Metabolomics of papillary thyroid carcinoma tissues: potential biomarkers for diagnosis and promising targets for therapy.
Shang X; Zhong X; Tian X
Tumour Biol; 2016 Aug; 37(8):11163-75. PubMed ID: 26935059
[TBL] [Abstract][Full Text] [Related]
11. Proteomic profiling of lung adenocarcinoma indicates heightened DNA repair, antioxidant mechanisms and identifies LASP1 as a potential negative predictor of survival.
Fahrmann JF; Grapov D; Phinney BS; Stroble C; DeFelice BC; Rom W; Gandara DR; Zhang Y; Fiehn O; Pass H; Miyamoto S
Clin Proteomics; 2016; 13():31. PubMed ID: 27799870
[TBL] [Abstract][Full Text] [Related]
12. A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics.
Farshidfar F; Weljie AM; Kopciuk KA; Hilsden R; McGregor SE; Buie WD; MacLean A; Vogel HJ; Bathe OF
Br J Cancer; 2016 Sep; 115(7):848-57. PubMed ID: 27560555
[TBL] [Abstract][Full Text] [Related]
13. Prediction of biomarkers of therapeutic effects of patients with lung adenocarcinoma treated with gefitinib based on progression-free-survival by metabolomic fingerprinting.
Zhuang J; Tang X; Du Z; Yang M; Zhou Y
Talanta; 2016 Nov; 160():636-644. PubMed ID: 27591660
[TBL] [Abstract][Full Text] [Related]
14. Identification of Proteomic Features To Distinguish Benign Pulmonary Nodules from Lung Adenocarcinoma.
Codreanu SG; Hoeksema MD; Slebos RJC; Zimmerman LJ; Rahman SMJ; Li M; Chen SC; Chen H; Eisenberg R; Liebler DC; Massion PP
J Proteome Res; 2017 Sep; 16(9):3266-3276. PubMed ID: 28731711
[TBL] [Abstract][Full Text] [Related]
15. Liquid Chromatography-Mass Spectrometry-Based Tissue Metabolic Profiling Reveals Major Metabolic Pathway Alterations and Potential Biomarkers of Lung Cancer.
You L; Fan Y; Liu X; Shao S; Guo L; Noreldeen HAA; Li Z; Ouyang Y; Li E; Pan X; Liu T; Tian X; Ye F; Li X; Xu G
J Proteome Res; 2020 Sep; 19(9):3750-3760. PubMed ID: 32693607
[TBL] [Abstract][Full Text] [Related]
16. Identification of proteins expressed differently among surgically resected stage I lung adenocarcinomas.
Ha ES; Choi S; In KH; Lee SH; Lee EJ; Lee SY; Kim JH; Shin C; Shim JJ; Kang KH; Phark S; Sul D
Clin Biochem; 2013 Mar; 46(4-5):369-77. PubMed ID: 23200884
[TBL] [Abstract][Full Text] [Related]
17. Metabolomics provide new insights on lung cancer staging and discrimination from chronic obstructive pulmonary disease.
Deja S; Porebska I; Kowal A; Zabek A; Barg W; Pawelczyk K; Stanimirova I; Daszykowski M; Korzeniewska A; Jankowska R; Mlynarz P
J Pharm Biomed Anal; 2014 Nov; 100():369-380. PubMed ID: 25213261
[TBL] [Abstract][Full Text] [Related]
18. Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites.
Di Gangi IM; Mazza T; Fontana A; Copetti M; Fusilli C; Ippolito A; Mattivi F; Latiano A; Andriulli A; Vrhovsek U; Pazienza V
Oncotarget; 2016 Feb; 7(5):5815-29. PubMed ID: 26735340
[TBL] [Abstract][Full Text] [Related]
19. 1H HR-MAS NMR spectroscopy of tumor-induced local metabolic "field-effects" enables colorectal cancer staging and prognostication.
Jiménez B; Mirnezami R; Kinross J; Cloarec O; Keun HC; Holmes E; Goldin RD; Ziprin P; Darzi A; Nicholson JK
J Proteome Res; 2013 Feb; 12(2):959-68. PubMed ID: 23240862
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
